BioNTech's Seoul Data Wins Over Analysts Even as Its CEO Keeps Trimming His Stake
Published on 09/17/2026 at 10:20 | Editorial boerse-global.de
BioNTech arrived at this week's World Conference on Lung Cancer in Seoul carrying a valuation debate it has yet to shake, and left with three separate analyst notes that answered the skeptics on clinical grounds rather than financial ones.
At the center of the attention is Gotistobart, a CTLA-4 antibody developed with partner OncoC4 and also known as BNT316/ONC-392. In the Phase III PRESERVE-003 trial, the drug produced a median overall survival of 18.5 months in patients with advanced squamous lung cancer who had already failed at least one prior therapy. The docetaxel chemotherapy comparator managed just 10 months. Response rates told a similar story: 20 percent against 4.8 percent, with tolerability described as comparable between the arms. Gotistobart already holds Fast Track and Orphan Drug designations from the FDA.
BioNTech also used the conference to present first-line small-cell lung cancer data for the combination of Pumitamig and Elfetabart. Berenberg pegged the response rate at 92 percent in first-line treatment, 76 percent in the second line, and still 52 percent among heavily pretreated patients. UBS analyst David Dai noted an absence of dose-limiting toxicities, with the discontinuation rate holding at a low 3.9 percent.
Three Houses, Three Higher Targets
The Street's response was swift and unanimous in direction. Dai reaffirmed his Buy rating with a $135 price target, pointing to an interim readout expected in 2026 and a possible regulatory filing in 2027. Jefferies' Akash Tewari kept his Buy rating and $138 target. Berenberg's Harry Gillis went furthest, lifting his target from $132 to $140. Berenberg assigns Pumitamig a peak sales potential of $5 billion at a 50 percent probability of success, with Elfetabart adding another $3 billion. The discontinued iNeST colorectal cancer vaccine program, once a pillar of the investment case, now sits further in the background.
Frankfurt, however, barely registered the enthusiasm. The shares closed Wednesday at EUR 83.60, down 0.2 percent on the previous day, hovering near their 50-day moving average of EUR 84.21 and roughly 21 percent below January's 52-week high of EUR 105.80. The muted German reaction stood in contrast to a firmer session in New York, where the stock gained more ground.
Should investors sell immediately? Or is it worth buying BioNTech?
Competition on the conference floor was hardly absent. Johnson & Johnson presented fresh survival data for its RYBREVANT regimen in EGFR-mutated lung cancer, while OncoC4 separately secured FDA Fast Track status for another candidate, Cesalatamig.
Insider Selling Runs on Autopilot
While the oncology narrative was being rewritten in Seoul, a separate disclosure stream was drawing quieter attention. CEO Ugur Sahin has continued selling company shares under a Rule 10b5-1 plan established back in June — an automated arrangement that lets insiders dispose of stock on a fixed schedule without any suggestion that they are trading on short-term inside information.
Since the start of September, Sahin has sold 289,000 shares, leaving him with 553,209 ordinary shares held directly and roughly 39.2 million more held indirectly through Medine GmbH. The recent disposals amount to a sliver of his overall holding, and the market's reaction to the filings has been subdued. Programmatic sales of this kind typically stem from tax or diversification motives rather than any verdict on the business outlook, and the timing here runs alongside a run of positive oncology headlines — the Seoul combination data being the latest.
Valuation Still the Open Question
Strip away the insider activity and the fundamental debate remains where it has been. BioNTech trades at a price-to-sales ratio of 7.9, below the biotech sector's roughly 12.5 and under the approximately 10.1 commanded by direct comparables. Even so, some observers still regard the multiple as demanding given the current revenue base.
The balance sheet offers room to maneuver. As of June 30, the company held EUR 16.6 billion in cash, enough to push several oncology programs forward in parallel while the core pipeline — Gotistobart in lung cancer and the Seoul combination therapy among them — works toward revenue generation over the medium term.
For shareholders, the takeaway is a familiar pairing: a solid balance sheet and clinical momentum as the real drivers, with the CEO's scheduled sales a footnote as long as his stake in the company remains essentially intact.
Ad
BioNTech Stock: New Analysis - 17 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
